IL299870A - Complement factor C3 inhibitors and their medical uses - Google Patents

Complement factor C3 inhibitors and their medical uses

Info

Publication number
IL299870A
IL299870A IL299870A IL29987023A IL299870A IL 299870 A IL299870 A IL 299870A IL 299870 A IL299870 A IL 299870A IL 29987023 A IL29987023 A IL 29987023A IL 299870 A IL299870 A IL 299870A
Authority
IL
Israel
Prior art keywords
inhibitors
complement factor
medical uses
medical
complement
Prior art date
Application number
IL299870A
Other languages
English (en)
Hebrew (he)
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of IL299870A publication Critical patent/IL299870A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
IL299870A 2020-07-16 2021-07-15 Complement factor C3 inhibitors and their medical uses IL299870A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
IL299870A true IL299870A (en) 2023-03-01

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299870A IL299870A (en) 2020-07-16 2021-07-15 Complement factor C3 inhibitors and their medical uses

Country Status (11)

Country Link
US (1) US20230287051A1 (cg-RX-API-DMAC10.html)
EP (1) EP4182023A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023538807A (cg-RX-API-DMAC10.html)
KR (1) KR20230039718A (cg-RX-API-DMAC10.html)
CN (1) CN116209671A (cg-RX-API-DMAC10.html)
AU (1) AU2021309548A1 (cg-RX-API-DMAC10.html)
CA (1) CA3185730A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001411A2 (cg-RX-API-DMAC10.html)
IL (1) IL299870A (cg-RX-API-DMAC10.html)
MX (1) MX2023000679A (cg-RX-API-DMAC10.html)
WO (1) WO2022013374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017385A2 (pt) 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品
CN122255228A (zh) * 2024-12-20 2026-06-23 重庆派金生物科技有限公司 靶向抑制c3与c5补体的双功能多肽、多肽偶联物及它们的应用
US20260234189A1 (en) 2025-01-24 2026-08-13 Boehringer Ingelheim International Gmbh Novel and stable compstatin analogues

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2751161B1 (en) * 2011-08-31 2018-09-19 Huntsmann Advanced Materials Licensing (Switzerland) GmbH Process for the impregnation of air core reactors, impregnated air core reactor and use of an impregnation system
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
ES3049784T3 (en) * 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
US20230287051A1 (en) 2023-09-14
CA3185730A1 (en) 2022-01-20
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CO2023001411A2 (es) 2023-02-16
CN116209671A (zh) 2023-06-02
JP2023538807A (ja) 2023-09-12
KR20230039718A (ko) 2023-03-21
WO2022013374A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
IL327523A (en) RAS inhibitors and methods of using them
IL318169A (en) Apol1 inhibitors and methods of use are the same
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL321357A (en) KIF18A inhibitors and their uses
IL304680A (en) Urolithin history and methods of using them
PL3799848T3 (pl) Wyroby chłonne i sposoby wytwarzania
IL314320A (en) Compounds and methods of use
IL312928A (en) Complement Factor B Modulating Preparations and Methods for Using Them
IL299840A (en) Inhibitors of complement factors and uses thereof
IL305789A (en) USP30 inhibitors and uses thereof
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
EP4110369A4 (en) TREATMENT METHODS AND RELATED COMPOSITIONS
IL318393A (en) Azaquinazoline compounds and methods of use
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL312583A (en) A preparation for the treatment and prevention of COVID-19
EP4329735A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
IL317288A (en) Inhibitors of expression and/or function
IL314277A (en) Anti-B7-H3 compounds and methods of use
GB202119051D0 (en) Wingsail and method of use
EP4119164A4 (en) ANTI-CORONAVIRUS EFFECT AND APPLICATION OF PI4K INHIBITOR
IL314164A (en) Inhibitors of complement factors and their uses
HK40093979A (en) Inhibitors of complement factor c3 and their medical uses
IL311518A (en) Preparations that modulate perkalkerine and methods of using them